The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8(+) T cells into innate-like effector cells with antitumor activity

od Wong, Hing C, Jeng, Emily K, Rhode, Peter R
Izdano 2013

Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC

od Basher, Fahmin, Jeng, Emily K., Wong, Hing, Wu, Jennifer
Izdano u Oncotarget (2015)

IL15N72D superagonist/IL15Rα-Fc fusion complex (ALT-803) exhibits anti-metastatic activity in murine breast tumor model

od Kim, Peter S, Kwilas, Anna R, Jeng, Emily K, Wong, Hing C, Schlom, Jeffrey, Hodge, James W
Izdano u J Immunother Cancer (2015)

IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-...

od Kim, Peter S., Kwilas, Anna R., Xu, Wenxin, Alter, Sarah, Jeng, Emily K., Wong, Hing C., Schlom, Jeffrey, Hodge, James W.
Izdano u Oncotarget (2016)

The IL-15 superagonist ALT-803 enhances anti-CD20 antibody-directed NK cell ADCC and in vivo clearance of B cell lymphomas

od Rosario, Maximillian, Liu, Bai, Kong, Lin, Schneider, Stephanie E, Jeng, Emily K, Rhode, Peter R, Wong, Hing C, Fehniger, Todd A
Izdano u J Immunother Cancer (2014)

Combinatorial therapy with an IL-15 superagonist (ALT-803) and anti-PD-L1 mAb augment T cell mediated anti-tumor immunity in mice

od Johnson, Christopher B, Riesenberg, Brian, Neitzke, Dan, Jeng, Emily K, Marcus, Warren D, Cole, David, Wong, Hing C, Rubinstein, Mark P
Izdano u J Immunother Cancer (2014)

Combination therapy of an IL-15 superagonist complex, ALT-803, and a tumor targeting monoclonal antibody promotes direct antitumor activity and protective vaccinal effect in a syng...

od Chen, Xiaoyue, Liu, Bai, Han, Kaiping, Kong, Lin, Noel, Terra, Jeng, Emily K, Alter, Sarah, Rubinstein, Mark, Rhode, Peter R, Wong, Hing C
Izdano u J Immunother Cancer (2015)

New interleukin-15 superagonist (IL-15SA) significantly enhances graft-versus-tumor activity

od Bailey, Cavan P., Budak-Alpdogan, Tulin, Sauter, Christopher T., Panis, Michelle M., Buyukgoz, Cihangir, Jeng, Emily K., Wong, Hing C., Flomenberg, Neal, Alpdogan, Onder
Izdano u Oncotarget (2017)

In Vivo Activation of Human NK Cells by Treatment with an Interleukin-15 Superagonist Potently Inhibits Acute In Vivo HIV-1 Infection in Humanized Mice

od Seay, Kieran, Church, Candice, Zheng, Jian Hua, Deneroff, Kathryn, Ochsenbauer, Christina, Kappes, John C., Liu, Bai, Jeng, Emily K., Wong, Hing C., Goldstein, Harris
Izdano u J Virol (2015)

Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model

od Mathios, Dimitrios, Park, Chul-Kee, Marcus, Warren D., Alter, Sarah, Rhode, Peter R., Jeng, Emily K., Wong, Hing C., Pardoll, Drew M., Lim, Michael
Izdano u Int J Cancer (2015)

Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models

od Liu, Bai, Jones, Monica, Kong, Lin, Noel, Terra, Jeng, Emily K., Shi, Sixiang, England, Christopher G., Alter, Sarah, Miller, Jeffrey S., Cai, Weibo, Rhode, Peter R., Wong, Hing C.
Izdano u Cytokine (2018)

Novel antitumor mechanism-of-action of an IL-2 fusion protein mediated by tumor associated macrophage repolarization and innate-like CD8+ memory T cells

od Xu, Wenxin, Egan, Jack O, Liu, Bai, Chen, Xiaoyue, You, Lijing, Han, Kaiping, Marcus, Warren D, Kong, Lin, Jones, Monica, Jeng, Emily K, Rhode, Peter R, Wong, Hing C
Izdano u J Immunother Cancer (2014)

Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15: Interleukin-15 Receptor α/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma

od Xu, Wenxin, Jones, Monica, Liu, Bai, Zhu, Xiaoyun, Johnson, C. Bryce, Edwards, Ana C., Kong, Lin, Jeng, Emily K., Han, Kaiping, Marcus, Warren D., Rubinstein, Mark P., Rhode, Peter R., Wong, Hing C.
Izdano 2013

A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses

od Liu, Bai, Kong, Lin, Han, Kaiping, Hong, Hao, Marcus, Warren D., Chen, Xiaoyue, Jeng, Emily K., Alter, Sarah, Zhu, Xiaoyun, Rubinstein, Mark P., Shi, Sixiang, Rhode, Peter R., Cai, Weibo, Wong, Hing C.
Izdano u J Biol Chem (2016)

Enhancing T cell therapy through TCR signaling-responsive nanoparticle drug delivery

od Tang, Li, Zheng, Yiran, de Melo, Mariane Bandeira, Mabardi, Llian, Castaño, Ana P., Xie, Yu-Qing, Li, Na, Kudchodkar, Sagar B., Wong, Hing C., Jeng, Emily K., Maus, Marcela V., Irvine, Darrell J.
Izdano u Nat Biotechnol (2018)

Enhanced lymphodepletion is insufficient to replace exogenous IL-2 or IL-15 therapy in augmenting the efficacy of adoptively transferred effector CD8(+) T cells

od Johnson, C. Bryce, May, Bennett R., Riesenberg, Brian P., Suriano, Samantha, Mehrotra, Shikhar, Garrett-Mayer, Elizabeth, Salem, Mohamed L., Jeng, Emily K., Wong, Hing C., Paulos, Chrystal M., Wrangle, John, Cole, David J., Rubinstein, Mark P.
Izdano u Cancer Res (2018)

ALT-803 Transiently Reduces Simian Immunodeficiency Virus Replication in the Absence of Antiretroviral Treatment

od Ellis-Connell, Amy L., Balgeman, Alexis J., Zarbock, Katie R., Barry, Gabrielle, Weiler, Andrea, Egan, Jack O., Jeng, Emily K., Friedrich, Thomas, Miller, Jeffrey S., Haase, Ashley T., Schacker, Timothy W., Wong, Hing C., Rakasz, Eva, O'Connor, Shelby L.
Izdano u J Virol (2018)

IL-15 AGONISTS OVERCOME THE IMMUNOSUPPRESSIVE EFFECTS OF MEK INHIBITORS

od Allegrezza, Michael J., Rutkowski, Melanie R., Stephen, Tom L., Svoronos, Nikolaos, Tesone, Amelia J., Perales-Puchalt, Alfredo, Nguyen, Jenny M., Sarmin, Fahmida, Sheen, Mee Rie, Jeng, Emily K., Tchou, Julia, Wong, Hing C., Fiering, Steven, Conejo-Garcia, Jose R.
Izdano u Cancer Res (2016)

Interleukin-15 Complex Treatment Protects Mice from Cerebral Malaria by Inducing Interleukin-10-Producing Natural Killer Cells

od Burrack, Kristina S., Huggins, Matthew A., Taras, Emily, Dougherty, Philip, Henzler, Christine M., Yang, Rendong, Alter, Sarah, Jeng, Emily K., Wong, Hing C., Felices, Martin, Cichocki, Frank, Miller, Jeffrey S., Hart, Geoffrey T., Johnson, Aaron J., Jameson, Stephen C., Hamilton, Sara E.
Izdano u Immunity (2018)

Glycolytic requirement for NK cell cytotoxicity and cytomegalovirus control

od Mah, Annelise Y., Rashidi, Armin, Keppel, Molly P., Saucier, Nermina, Moore, Emily K., Alinger, Joshua B., Tripathy, Sandeep K., Agarwal, Sandeep K., Jeng, Emily K., Wong, Hing C., Miller, Jeffrey S., Fehniger, Todd A., Mace, Emily M., French, Anthony R., Cooper, Megan A.
Izdano u JCI Insight (2017)